BridgeBio Pharma (NASDAQ:BBIO) Issues Quarterly Earnings Results

BridgeBio Pharma (NASDAQ:BBIO) issued its quarterly earnings data on Thursday. The company reported ($0.51) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.55) by $0.04, Yahoo Finance reports. The firm had revenue of $26.74 million for the quarter.

Shares of BBIO traded up $2.64 during mid-day trading on Friday, hitting $27.06. 290,200 shares of the company traded hands, compared to its average volume of 279,343. BridgeBio Pharma has a one year low of $17.61 and a one year high of $32.94. The business has a 50-day simple moving average of $20.94.

Several analysts have weighed in on BBIO shares. Goldman Sachs Group started coverage on shares of BridgeBio Pharma in a research note on Monday, July 22nd. They set a “buy” rating and a $42.00 price objective on the stock. Raymond James started coverage on shares of BridgeBio Pharma in a research note on Friday, July 26th. They set an “outperform” rating and a $36.00 price objective on the stock. Zacks Investment Research cut shares of BridgeBio Pharma from a “hold” rating to a “sell” rating in a research note on Tuesday. Leerink Swann started coverage on shares of BridgeBio Pharma in a research note on Monday, July 22nd. They set an “outperform” rating and a $34.00 price objective on the stock. Finally, BMO Capital Markets started coverage on shares of BridgeBio Pharma in a research note on Monday, July 22nd. They set an “outperform” rating and a $49.00 price objective on the stock. One research analyst has rated the stock with a sell rating and eight have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $40.13.

About BridgeBio Pharma

BridgeBio Pharma, Inc finds, develops, and delivers various medicines for genetic diseases. The company has a pipeline of 15 development programs that include product candidates ranging from early discovery to late-stage development in various therapeutic areas, including genetic dermatology, oncology, cardiology, neurology, endocrinology, renal disease, and ophthalmology.

Featured Article: What is the Beige Book?

Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.